{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:39:32Z","timestamp":1777934372963,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Multiple myeloma is a chronic, uncurable hematological cancer with the involvement of multiple organ systems. As a disease affecting older patients, the treatment of multiple myeloma should be based on individual patient characteristics. Polypharmacy is an increasing problem in the care of older patients and in patients with multiple myeloma, polypharmacy is almost inevitable. We aimed to evaluate the applicability of polypharmacy definitions and the relation of polypharmacy with disease outcomes in patients with multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty patients older than 65 years and diagnosed with multiple myeloma were retrospectively enrolled. Patient files, prescriptions, evaluations for polypharmacy were determined according to Beers and START\/STOPP criteria. Outcomes were recorded from files in terms of fractures, autonomous neuropathy, and renal functions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Polypharmacy with\u2009\u22654 drugs was observed in 65 patients while polypharmacy with \u22655 drugs was observed in 51 patients. Autonomous neuropathy, polypharmacy with more than four or five medications, and use of multiple medications in the same category were related with poor ECOG performance status in women, while prolonged use of benzodiazepines and central nervous system (CNS) affecting drugs and inappropriate polypharmacy were more frequent in men with poor ECOG performance status. The majority of patients aged 75\u201384 years were observed to use inappropriate polypharmacy. Autonomous neuropathy and fall risk were observed to be significantly related with inappropriate polypharmacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Drugs affecting balance and perception should be reconsidered in patients with multiple myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155219835303","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T21:25:27Z","timestamp":1553030727000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5589-3000","authenticated-orcid":false,"given":"Elif G","family":"Um\u0131t","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Department of Hematology, Trakya University, Edirne, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Baysal","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Hematology, Trakya University, Edirne, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volkan","family":"Bas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Hematology, Trakya University, Edirne, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Asker","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Hematology, Trakya University, Edirne, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"K\u0131rk\u0131zlar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Hematology, Trakya University, Edirne, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet M","family":"Dem\u0131r","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Hematology, Trakya University, Edirne, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"bibr1-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291"},{"key":"bibr2-1078155219835303","unstructured":"American Cancer Society.\n                      Cancer Facts & Figures 2019\n                      . Atlanta, GA: American Cancer Society, 2019."},{"key":"bibr3-1078155219835303","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0426"},{"key":"bibr4-1078155219835303","unstructured":"National Cancer Institute. Surveillance, epidemiology and end results program. SEER Stat Fact Sheets:\n                      Myeloma\n                      , 11 January 2018."},{"key":"bibr5-1078155219835303","unstructured":"Turk Hematoloji Dernegi Multipl Miyelom Tedavi K\u217clavuzu [Turkish Society of Hematology National Guideline for the Diagnosis and Management of Multiple Myeloma 2016]. Ankara, Turkey: Turkish Society of Hematology, 2016."},{"key":"bibr6-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"bibr7-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2"},{"key":"bibr8-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.827660"},{"key":"bibr9-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-014-0229-8"},{"key":"bibr10-1078155219835303","doi-asserted-by":"crossref","unstructured":"American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015. Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.\n                      J Am Geriatr Soc\n                      2015; 63(11): 2227\u201346.","DOI":"10.1111\/jgs.13702"},{"key":"bibr11-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afu145"},{"key":"bibr12-1078155219835303","doi-asserted-by":"publisher","DOI":"10.14694\/EDBK_159009"},{"key":"bibr13-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"bibr14-1078155219835303","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2010.13500"},{"key":"bibr15-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1111\/ajag.12476"},{"key":"bibr16-1078155219835303","doi-asserted-by":"crossref","unstructured":"Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society. Summary of the Updated American Geriatrics Society\/British Geriatrics Society clinical practice guideline for prevention of falls in older persons.\n                      J Am Geriatr Soc\n                      2011; 59(1): 148\u201357.","DOI":"10.1111\/j.1532-5415.2010.03234.x"},{"key":"bibr17-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"bibr18-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1365859"},{"key":"bibr19-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000395"},{"key":"bibr20-1078155219835303","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148189"},{"key":"bibr21-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.3.327"},{"key":"bibr22-1078155219835303","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12741"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219835303","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219835303","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219835303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:20:55Z","timestamp":1777688455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219835303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1177\/1078155219835303"],"URL":"https:\/\/doi.org\/10.1177\/1078155219835303","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]}}}